VIR · Vir Biotechnology, Inc.
Price & Indicators
Up next
Latest filings
Vir Biotechnology, Inc. expanded its board from eight to nine members and appointed Suzanne Topalian, M.D. as a Class III director, effective October 27, 2026, and to its Science and Technology Committee through the 2028 annual meeting.
Read the 8-KMetrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Vir Biotechnology reported Q2 2026 results highlighted by $80.1M net income driven by a $240M Astellas upfront payment, completed enrollment across all three Phase 3 ECLIPSE hepatitis delta registrational trials with Eclipse 1 topline data expected in Q4 2026, and Phase 2 SOLSTICE Week 96 data showing 88% HDV RNA target-not-detected with elebsiran plus tobevibart.
- + Completed enrollment across all three Phase 3 ECLIPSE registrational trials in chronic hepatitis delta, with Eclipse 1 topline data expected Q4 2026.
- + Phase 2 SOLSTICE Week 96 data showed 88% HDV RNA target-not-detected rate with elebsiran plus tobevibart versus 53% on antibody monotherapy.
- + Closed Astellas collaboration and initiated multiple VIR-5500 Phase 1 monotherapy and combination dose-expansion cohorts, with pivotal Phase 3 planned for 2027.
- + Cash position increased by $198.5M to approximately $1.01 billion, with runway projected into second half of 2028.
- + Reported Q2 net income of $80.1M, or $0.48 per share basic, versus a net loss of $111.0M in Q2 2025.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VIR
this stock
Vir Biotechnology, Inc.
|
$1.88B | +91.9% | -7.6% | — | 9.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.7% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 28, 2026
- This year
- 23
Vir Biotechnology, Inc. expanded its board from eight to nine members and appointed Suzanne Topalian, M.D. as a Class III director, effective October 27, 2026, and to its Science and Technology Committee through the 2028 annual meeting.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VIR | +7.7% | +8.6% | +12.4% | +3.5% | +91.9% |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | +7.7% | +7.9% | +7.6% | +2.6% | +79.0% |